VSTM — Verastem Inc

Verastem Inc (VSTM) is a biotechnology company listed on NASDAQ. It is led by Daniel W. Paterson, based in 117 Kendrick Street, Needham, MA, United States, 02494, with about 78 employees. Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Latest reported VSTM revenue for 2025-09-30 was $11.2M. Net income was -$176.6M. Revenue was up 426.1% from 2025-06-30 to 2025-09-30. VSTM currently screens at market cap $264.3M.

Use this VSTM page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the VSTM quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the VSTM SEC filings page. Lician reads the product cache first so this HTML stays unique to Verastem Inc even when a live quote feed is slow.